Cefotetan Disodium
The disodium salt formulation of cefotetan is used parenterally for the treatment and prophylaxis of polymicrobial infections with anaerobic components. It shares the cephamycin-class activity and the associated coagulation risks of the parent compound. Vitamin K levels should be monitored in patients on prolonged courses.
分子量
619.6000 g/mol
TPSA
327.00 Ų
作用机制
Serves as an essential micronutrient cofactor in various enzymatic reactions and metabolic processes. Supplementation corrects deficiency states and supports normal physiological function.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Serves as an essential micronutrient cofactor in various enzymatic reactions and metabolic processes. Supplementation corrects deficiency states and supports normal physiological function.
二维结构
Cite this structure
Embed this structure
SMILES
CO[C@@]1(NC(=O)C2SC(=C(C(N)=O)C(=O)[O-])S2)C(=O)N2C(C(=O)[O-])=C(CSc3nnnn3C)CS[C@@H]21.[Na+].[Na+]
InChI
InChI=1S/C17H17N7O8S4.2Na/c1-23-16(20-21-22-23)34-4-5-3-33-15-17(32-2,14(31)24(15)7(5)11(29)30)19-9(26)13-35-12(36-13)6(8(18)25)10(27)28;;/h13,15H,3-4H2,1-2H3,(H2,18,25)(H,19,26)(H,27,28)(H,29,30);;/q;2*+1/p-2/b12-6-;;/t13?,15-,17+;;/m1../s1
Molecular Formula
C17H15N7Na2O8S4
HBD / HBA
2 / 15
可旋转键数
7
重原子数
38
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
常见问题
The disodium salt formulation of cefotetan is used parenterally for the treatment and prophylaxis of polymicrobial infections with anaerobic components. It shares the cephamycin-class activity and the associated coagulation risks of the parent compound. Vitamin K levels should be monitored in patients on prolonged courses.
Serves as an essential micronutrient cofactor in various enzymatic reactions and metabolic processes. Supplementation corrects deficiency states and supports normal physiological function.
Yes, Cefotetan Disodium is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201098. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 53024. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="cefotetan-disodium"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/cefotetan-disodium/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/cefotetan-disodium/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/cefotetan-disodium/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="cefotetan-disodium"></drugfyi-drug>